Meeting
2019 ASCO Annual Meeting
Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Giulia Baciarello
Department of Cancer Medicine, Gustave Roussy Cancer Campus, Paris-Sud University, France, Villejuif, France
Giulia Baciarello , Remy Delva , Gwenaelle Gravis , Youssef Tazi , Christine Theodore , Marine Gross-Goupil , Emmanuelle Bompas , Florence Joly , Tifenn Lharidon , Thierry Nguyen Tan Hon , Philippe Barthelemy , Stephane Culine , Jean Francois Berdah , Mathilde Deblock , Philippe Beuzeboc , Aude Flechon , Caroline Cheneau , Geraldine Martineau , Isabelle Borget , Karim Fizazi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02044354
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5017)
DOI
10.1200/JCO.2019.37.15_suppl.5017
Abstract #
5017
Poster Bd #
129
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
First Author: Susan Halabi
Poster
2020 Genitourinary Cancers Symposium
Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
First Author: Antonin Broyelle
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson